In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery.

导出 LinkOut

翻译打印收藏纠错

作者： Cort B,Breuer ^[1] ; Killian S,Hanlon ^[2] ; Jeya-Shree,Natasan ^[3] ; Adrienn,Volak ^[2] ; Amine,Meliani ^[2] ; Federico,Mingozzi ^[4] ; Benjamin P,Kleinstiver ^[5] ; James J,Moon ^[4] ; Casey A,Maguire ^[5]

作者单位： Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA, USA. ^[1] Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. ^[2] Department of Neurobiology, Harvard Medical School, Boston, MA, USA. ^[3] Genethon, INSERM UMR S951, Evry, France. ^[4] Sorbonne University, INSERM U974, Paris, France. ^[5] Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. ^[6] Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. ^[7] Department of Pathology, Harvard Medical School, Boston, USA. ^[8] Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA, USA. jjmoon@mgh.harvard.edu. ^[9] Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Charlestown, MA, USA. jjmoon@mgh.harvard.edu. ^[10] Harvard Medical School, Boston, MA, USA. jjmoon@mgh.harvard.edu. ^[11] Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. cmaguire@mgh.harvard.edu. ^[12] Harvard Medical School, Boston, MA, USA. cmaguire@mgh.harvard.edu. ^[13]